Anixa Biosciences (ANIX) Short term Debt (2014 - 2017)

Anixa Biosciences' (ANIX) quarterly Short term Debt came in at $2.0 million in Q3 2017, down 33.33% on a QoQ basis from $3.0 million in Q2 2017.

Anixa Biosciences (ANIX) Short term Debt (2014 - 2017) Analysis & Trends

Anixa Biosciences (ANIX) has 2 years of Short term Debt data on file, last reported at $2.0 million in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Anixa Biosciences	121.44 Mn	121.44 Mn	-

Download Data